{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T06:07:01Z","timestamp":1789020421330,"version":"build-2803163510"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T00:00:00Z","timestamp":1788998400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>This study compared the effectiveness and safety profiles of systemic glucocorticoids (sGCs) and Nefecon in the treatment of patients with immunoglobulin A nephropathy (IgAN).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with IgAN who had an estimated glomerular filtration rate (eGFR) \u2265 15 mL\/min\/1.73 m\u00b2 and were treated with sGCs or Nefecon were included. The primary outcome was defined as a \u2265 30% reduction in the urine protein-to-creatinine ratio (UPCR) and a combination of partial or complete remission at 12 months. Analysis of variance (ANOVA) with a mixed-effects model and t-tests was used to compare the therapeutic effectiveness and safety profiles of sGCs and Nefecon.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and eight patients with IgAN were included in the study, with 54 patients receiving sGCs and 54 patients receiving Nefecon. For efficacy, the mean annual change in UPCR after treatment (sGCs versus Nefecon) was \u221232.01% versus \u221250.34%, P = 0.007. The total remission rate at 12 months (sGCs versus Nefecon) was 29.63% versus 61.11%. The percentage of patients with a \u2265 30% decline in UPCR at 12 months (sGCs versus Nefecon) was 68.52% versus 90.74%. The mean 12-month change in eGFR after treatment (sGCs versus Nefecon) was 0 versus 2.28 mL\/min\/1.73 m\u00b2, P\u00a0=\u00a00.266. The median annualized change in eGFR after treatment (sGCs versus Nefecon) was \u22122.31 [\u22127.49, 3.75] versus 1.36 [\u22121.23, 6.53] mL\/min\/1.73 m\u00b2, P\u00a0=\u00a00.002. For safety, in sGCs group, there are 3 MAKEs events while no MAKEs event in Nefecon group. Eight patients experienced severe adverse events in the sGCs group, compared with only one patient in the Nefecon group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study demonstrated that Nefecon had greater efficacy than sGCs at 12 months and a more favorable safety profile in patients with IgAN, although confirmation in larger prospective studies with longer follow-up is warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1865905","type":"journal-article","created":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:20Z","timestamp":1789018280000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of efficacy and safety of systemic glucocorticoids and Nefecon in IgA nephropathy patients: a real-world retrospective cohort study"],"prefix":"10.3389","volume":"17","author":[{"given":"Chenjie","family":"Gu","sequence":"first","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingying","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Kang","sequence":"additional","affiliation":[{"name":"Medical College of Dalian University","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, The First Affiliated Hospital of Dalian Medical University, Renal Translational Medicine Center of Liaoning Province","place":["Dalian, Liaoning, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41572-023-00476-9","article-title":"IgA nephropathy","volume":"9","author":"Stamellou","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.07420716","article-title":"IgA nephropathy","volume":"12","author":"Rodrigues","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfaf084","article-title":"CKD progression, kidney failure, and mortality among US patients with IgA nephropathy","volume":"40","author":"Sim","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1681\/asn.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.5368","article-title":"Effect of oral methylprednisolone on decline in kidney function or kidney failure in patients with IgA nephropathy: The TESTING randomized clinical trial","volume":"327","author":"Lv","year":"2022","journal-title":"JAMA"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1461879","article-title":"Therapy of IgA nephropathy: time for a paradigm change","volume":"11","author":"Barratt","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2008.08.001","article-title":"How host-bacterial interactions lead to IgA synthesis in the gut","volume":"29","author":"Suzuki","year":"2008","journal-title":"Trends Immunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjms.2020.10.003","article-title":"IgA nephropathy: An interesting autoimmune kidney disease","volume":"361","author":"Rajasekaran","year":"2021","journal-title":"Am J Med Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)01554-4","article-title":"Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trial","volume":"402","author":"Lafayette","year":"2023","journal-title":"Lancet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.04.004","article-title":"KDIGO 2025 clinical practice guideline for the management of immunoglobulin A nephropathy (IgAN) and immunoglobulin A vasculitis (IgAV)","volume":"108","author":"Rovin","year":"2025","journal-title":"Kidney Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf324","article-title":"The 2025 KDIGO IgA nephropathy guideline update: an ERA Immunonephrology Working Group perspective","volume":"18","author":"Stamellou","year":"2025","journal-title":"Clin Kidney J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaf203","article-title":"Predictive value of Gd-IgA1, poly-IgA in the treatment of IgA nephropathy with targeted-release formulation budesonide","volume":"18","author":"Chen","year":"2025","journal-title":"Clin Kidney J"},{"key":"B13","doi-asserted-by":"publisher","first-page":"6621","DOI":"10.3390\/jcm13216621","article-title":"IgA vasculitis (Henoch-Sch\u00f6nlein purpura): An update on treatment","volume":"13","author":"Casta\u00f1eda","year":"2024","journal-title":"J Clin Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1080\/1744666x.2023.2206119","article-title":"Budesonide delayed-release capsules to reduce proteinuria in adults with primary immunoglobulin A nephropathy","volume":"19","author":"Barratt","year":"2023","journal-title":"Expert Rev Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.kint.2022.09.017","article-title":"Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy","volume":"103","author":"Barratt","year":"2023","journal-title":"Kidney Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2026.1761804","article-title":"Efficacy and safety of Nefecon in IgA nephropathy: real world clinical practice","volume":"17","author":"Zhai","year":"2026","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41581-024-00885-3","article-title":"The pathogenesis of IgA nephropathy and implications for treatment","volume":"21","author":"Cheung","year":"2025","journal-title":"Nat Rev Nephrol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfae404","article-title":"eGFR slope modelling predicts long-term clinical benefit with nefecon in a real-world IgAN population","volume":"18","author":"Barratt","year":"2025","journal-title":"Clin Kidney J"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e42729","article-title":"Targeted-release budesonide: a comprehensive review on its potential in IgA nephropathy","volume":"11","author":"Qi","year":"2025","journal-title":"Heliyon"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2024.07.006","article-title":"Exploring novel adverse events of Nefecon","volume":"9","author":"Wang","year":"2024","journal-title":"Kidney Int Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1538074","article-title":"Machine learning modeling for the risk of acute kidney injury in inpatients receiving amikacin and etimicin","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Pharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-025-01981-5","article-title":"Clinical risk assessment of serum creatinine abnormalities during vancomycin therapy: a retrospective study using machine learning models","volume":"47","author":"Yang","year":"2025","journal-title":"Int J Clin Pharm"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865905\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:31:20Z","timestamp":1789018280000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1865905\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":22,"alternative-id":["10.3389\/fimmu.2026.1865905"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1865905","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"1865905"}}